CV 3988
Alternative Names: CHX 3988Latest Information Update: 08 Nov 2000
At a glance
- Originator Takeda
- Class Antiplatelets
- Mechanism of Action Platelet activating factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Coronary disorders; Thrombosis
Most Recent Events
- 08 Nov 2000 Discontinued - preclinical in Coronary disorders in Germany (Unknown route)
- 08 Nov 2000 Discontinued - preclinical in Coronary disorders in USA (Unknown route)
- 08 Nov 2000 Discontinued - Unspecified phase in Thrombosis in Belgium (Unknown route)